Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits

This review describes our current understanding of the role of the mitochondria in the repurposing of the anti-diabetes drugs metformin, gliclazide, GLP-1 receptor agonists, and SGLT2 inhibitors for additional clinical benefits regarding unhealthy aging, long COVID, mental neurogenerative disorders,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2025-01, Vol.26 (1), p.364
Hauptverfasser:	Yip, Joyce Mei Xin, Chiang, Grace Shu Hui, Lee, Ian Chong Jin, Lehming-Teo, Rachel, Dai, Kexin, Dongol, Lokeysh, Wang, Laureen Yi-Ting, Teo, Denise, Seah, Geok Teng, Lehming, Norbert
Format:	Artikel
Sprache:	eng
Schlagworte:	Aging Animals Autophagy Biosynthesis Cancer Chronic illnesses COVID-19 - metabolism COVID-19 - virology COVID-19 Drug Treatment Diabetes Diabetes Mellitus - drug therapy Diabetes Mellitus - metabolism Disease Drug Repositioning - methods Drugs Enzymes Fatty acids Glucose Homeostasis Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin Kinases Long COVID Metabolism Metformin - pharmacology Metformin - therapeutic use Mitochondria Mitochondria - drug effects Mitochondria - metabolism Mitochondrial DNA Off-Label Use Pancreas Peptides Phosphorylation Proteins Quality control Review SARS-CoV-2 - drug effects Senescence
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!